Adalimumab with immunomodulator (Crohn)

  Crohn, IBD

Adalimumab with immunomodulator in Crohn


Related articles (Crohn):
*
Azathioprine Crohn
*Methotrexate in Crohn
*Infliximab in Crohn (ACCENT I)
*Infliximab with Azathiopurine (Crohn)
*Infliximab with Methotrexate (Crohn)
*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)
*Adalimumab (CLASSIC & CHARM trial – Crohn)
*Ustekinumab (UNITI trial – Crohn – 2016)
*Vedolizumab (GEMINI II – Crohn – 2013)


Combination therapy anti-TNF (in this case Adalimumab/Humira) with immunomodulator, mostly azathiopurine. Studies below show comparison between monotherapy Adalimumab and combinations with immunomodulator. The aim is to reduce antibody formation in the induction phase.

References:

Uri Kopylov, Talal Al-Taweel, Mohammad Yaghoobi, Benedicte Nauche, Alain Bitton, Peter L. Lakatos, Shomron Ben-Horin, Waqqas Afif, Ernest G. Seidman, Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn’s disease: A systematic review and meta-analysis, Journal of Crohn’s and Colitis, Volume 8, Issue 12, 1 December 2014, Pages 1632–1641, https://doi.org/10.1016/j.crohns.2014.07.003

Takayuki Matsumoto, Satoshi Motoya, Kenji Watanabe, Tadakazu Hisamatsu, Hiroshi Nakase, Naoki Yoshimura, Tetsuya Ishida, Shingo Kato, Tomoo Nakagawa, Motohiro Esaki, Masakazu Nagahori, Toshiyuki Matsui, Yuji Naito, Takanori Kanai, Yasuo Suzuki, Masanori Nojima, Mamoru Watanabe, Toshifumi Hibi, for the DIAMOND study group, Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial, Journal of Crohn’s and Colitis, Volume 10, Issue 11, November 2016, Pages 1259–1266, https://doi.org/10.1093/ecco-jcc/jjw152